Precision medicine software platform Sano Genetics announced an $11.4 million raise led by Plural. Sano Genetics is the only software platform for conducting precision medicine clinical trials. It utilises artificial intelligence to manage all aspects from design to patient recruitment, genetic and other biomarker testing and patient engagement. It is leading the financing with participation from existing investors including Plural, MMC Ventures, Episode 1 Ventures and Seedcamp.
Precision medicine is changing the way we think about and approach healthcare. Clinical trials are at the heart of precision medicine development. In the past 12 months, we have increased our capacity to run three times as many trials as the previous year and launched our first programme supporting families affected by ALS. I’m delighted with everything the team has achieved so far, and this new funding will help us drive greater productivity by integrating big language models and other AI tools. This will help us continue on our growth trajectory, especially with the help of visionary investors like Carina Namih, who supported our seed round and is now backing us again at Plural.Patrick Short, co-founder and CEO of Sano Genetics
Precision medicine is a rapidly growing category. Today, more than 30 per cent of trials are precision-focused and it is estimated to reach 80 per cent by the end of the decade. Precision medicine marks a generational shift in drug development. This is because clinical trials using genetic data have a 26 per cent success rate, compared to 10 per cent in standard clinical trials. Sano Genetics connects patients in four countries, including the UK, USA, Australia and Canada, with pharmaceutical and biotechnology companies conducting clinical trials. It also makes it easier for patients to access precision medical treatment and for companies to bring new, effective medicines to market quickly.
It offers a digital matching experience for the conduct of clinical trials. It is quick and seamless for customers to upload their new trials to the Sano platform and include criteria for the patients they are looking for. Sano Genetics then supports the recruitment of suitable patients, including advertising through social media and healthcare providers. It also engages participants up to three times faster than traditional methods. They use Sano’s platform to manage all aspects of the trial, including participant communication, facilitating genetic and other biomarker testing, returning results and even supporting patients with genetic counselling. This is all delivered through the platform’s consumer-grade interface that prioritises security and compliance.
In addition, Sano Genetics will use the new funding to run similar programmes to take charge of predictive and preventive genetics as part of its mission to accelerate the future of precision medicine. It brings the total raised by the company to $22 million. It will be used to meet the growing demand for its products, to further leverage artificial intelligence and expand its reach to even more countries, and to become the ultimate precision trial platform.